Kazia Therapeutics (KZIA) Stock Statistics & Valuation Metrics

Kazia Therapeutics has a market cap or net worth of $9.73M. The enterprise value is ―.

Kazia Therapeutics has 1,359,626 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kazia Therapeutics’s return on equity (ROE) is 2.67 and return on invested capital (ROIC) is 787.50%.

The current PE Ratio of Kazia Therapeutics is ―. Kazia Therapeutics’s PEG ratio is 0.00.

In the last 12 months, Kazia Therapeutics had revenue of 2.31M and earned -26.78M in profits. Earnings per share was -55.00.

In the last 12 months, operating cash flow was -7.46M and capital expenditures 0.00, giving a free cash flow of -7.46M billion.

Kazia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Kazia Therapeutics upcoming earnings date is Aug 28, 2025, TBA (Confirmed).

Kazia Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -3.70%

In the past 12 months, Kazia Therapeutics has paid -271.00K in taxes.

Kazia Therapeutics EV to EBITDA ratio is -0.25, with an EV/FCF ratio of -0.71.

Kazia Therapeutics has $3.06M in cash and marketable securities with $140.74K in debt, giving a net cash position of $2.92M billion.

Gross margin is 100.00%, with operating margin of -1233.19%, and net profit margin of -1160.23%.

The average price target for Kazia Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy